期刊
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
卷 14, 期 9, 页码 1091-1103出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17512433.2021.1938548
关键词
Testosterone; diabetes; metabolic syndrome; obesity; hypogonadism
Data from preclinical and clinical studies suggest that testosterone administration can improve body composition and aspects of glucose metabolism by reducing fat mass. The effects of testosterone replacement therapy on sexual function in patients with metabolic derangements are inconsistent, with better results observed in preclinical conditions or in patients with newly diagnosed type 2 diabetes mellitus.
Introduction The specific role of testosterone [T] replacement therapy [TRT] on glycometabolic profile and body composition, particularly in patients with metabolic syndrome [MetS] and/or type 2 diabetes mellitus [T2DM], is still the object of an intense debate. Areas covered To discuss available evidence on the association between T and metabolic diseases and on the possible effect of T administration on metabolic disorder-associated hypogonadism. Both preclinical and clinical data have been considered. In addition, a meta-analysis of the available placebo and non-placebo-controlled randomized clinical trials [RCTs] investigating the effects of TRT in T2DM or MetS in several outcomes has been also performed. Expert opinion Data derived from preclinical and clinical studies suggest that T administration, by reducing fat mass, can improve body composition and ameliorate some aspects of glucose metabolism. The effects of TRT on sexual function in patients with established metabolic derangements are inconsistent, whereas better results were observed in preclinical conditions or in patients with newly diagnosed T2DM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据